- Home
- AUST vs QNCX Comparison
AUST vs QNCX Comparison
Compare AUST & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | QNCX |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 19.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AUST | QNCX |
|---|---|---|
| Price | $1.23 | $1.08 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 62.9K | ★ 1.5M |
| Earning Date | 05-06-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $0.08 |
| 52 Week High | $3.92 | $4.55 |
Technical Indicators
Market Signals| Indicator | AUST | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 35.13 | 49.53 |
| Support Level | N/A | $0.10 |
| Resistance Level | $1.59 | $1.50 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 14.58 | 50.89 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration, and evaluation of mineral resource properties in the western United States of America (USA). The exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek, Lone Mountain, Stockade Mountain, Fourmile Basin, and Miller.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.